TrumpRx and Cost Plus Drugs: A New Era for Prescription Drug Pricing

The landscape of prescription drug pricing is undergoing a significant shift with the emergence of two key players: TrumpRx, a government-run platform, and Cost Plus Drugs, a digital pharmaceutical marketplace founded by Mark Cuban. Both initiatives aim to lower costs by eliminating traditional intermediaries, but they approach the challenge with different models. This article examines the details of each platform, their potential impact on consumers, and the recent partnership between Cost Plus Drugs and TrumpRx.

Understanding TrumpRx

President Donald Trump announced the development of TrumpRx, scheduled to launch in early 2026. The platform will allow uninsured Americans to purchase brand-name medications directly from manufacturers at discounted prices. TrumpRx aims to bypass Pharmacy Benefit Managers (PBMs), which have historically contributed to higher drug costs.

Cost Plus Drugs: A Disruptor in the Market

Launched in 2022 by Mark Cuban, Cost Plus Drugs operates as a digital pharmaceutical marketplace. The company primarily focuses on offering generic medications, with a limited selection of brand-name drugs. Cost Plus Drugs adds a 15% markup to the direct purchase cost of medications, plus a $5 pharmacy charge and a $5 shipping fee. This transparent pricing model aims to provide significant savings, particularly for those without insurance or with high deductibles.

Key Differences Between the Platforms

While both TrumpRx and Cost Plus Drugs share the goal of reducing prescription drug costs, their approaches differ:

• Discount Model: Cost Plus Drugs adds a fixed 15% markup, while TrumpRx offers discounts negotiated directly with manufacturers.
• Drug Availability: Cost Plus Drugs currently focuses on generics, while TrumpRx will offer brand-name medications.
• Target Audience: Both platforms target uninsured individuals, but TrumpRx specifically focuses on this demographic.

The Partnership: Cost Plus Drugs and TrumpRx

In December 2025, Mark Cuban announced a partnership between Cost Plus Drugs and TrumpRx. As part of this collaboration, Cost Plus Drugs will share access to its programming interface with TrumpRx. This will enable the government-run platform to access real-time pricing data for medications available through Cost Plus Drugs, increasing price transparency and allowing consumers to compare costs effectively.

Mark Cuban’s Perspective

Mark Cuban has publicly supported the TrumpRx initiative, giving it a “B” grade and stating it would be beneficial for patients. He as well noted that TrumpRx is saving people money on some drugs.

Looking Ahead

The launch of TrumpRx in January 2026, coupled with the partnership with Cost Plus Drugs, represents a potentially transformative moment for prescription drug pricing. Increased price transparency and competition are expected to benefit consumers, particularly those who are uninsured or underinsured. The success of these initiatives will depend on their real-world functionality and the extent to which they can deliver on their promise of lower drug costs.